chrisvoncsefalvay/vaers-outcomes huggingface dataset:
AFTER THE PATIENT LEFT THE PHARMACY SHE NOTICED A RED SPOT ON THE FACE THAT SOON WENT AWAY. NO OTHER SYMPTOMS WERE NOTED UNTIL SHE WOKE UP THE NEXT MORNING. PATIENT BROKE OUT IN A RASH AND THICK HIVES ON EXTREMITIES. SHE ALSO HAD SWELLING IN HER FEET AND HANDS. SHE SOUGHT CARE AT THE WEEKEND CLINIC. EXAMINATION SHOWED RASH ON EXTREMITIES AND IT WAS NOT CONCENTRATED ON ONE ARM, ONE SIDE OF THE BODY OR THE OTHER. PREDNISONE WAS PRESCRIBED AND PATIENT WAS TOLD TO TAKE BENADRYL OTC.
on Tuesday of the next day after the vaccine shot I couldn't use my raise or lift my left arm and it was swollen and I was very fatigue
Misalignment of jaws; increasing and progressive swelling; Joint stiffness; Joint swelling; limited use & range of motion; Swollen feet; Painful feet; Exacerbated Neurological condition; sore joints / joint pain; This spontaneous case was reported by a consumer and describes the occurrence of JOINT DISLOCATION (Misalignment of jaws), SWELLING (increasing and progressive swelling), JOINT STIFFNESS (Joint stiffness), JOINT SWELLING (Joint swelling) and MOBILITY DECREASED (limited use & range of motion) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 019B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event (No medical history reported.).    On 29-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-Mar-2021, the patient experienced ARTHRALGIA (sore joints / joint pain). On 03-Apr-2021, the patient experienced JOINT DISLOCATION (Misalignment of jaws), SWELLING (increasing and progressive swelling), JOINT STIFFNESS (Joint stiffness), JOINT SWELLING (Joint swelling), MOBILITY DECREASED (limited use & range of motion), PERIPHERAL SWELLING (Swollen feet), PAIN IN EXTREMITY (Painful feet) and NERVOUS SYSTEM DISORDER (Exacerbated Neurological condition). At the time of the report, JOINT DISLOCATION (Misalignment of jaws), SWELLING (increasing and progressive swelling), JOINT STIFFNESS (Joint stiffness), JOINT SWELLING (Joint swelling), MOBILITY DECREASED (limited use & range of motion), PERIPHERAL SWELLING (Swollen feet), PAIN IN EXTREMITY (Painful feet), NERVOUS SYSTEM DISORDER (Exacerbated Neurological condition) and ARTHRALGIA (sore joints / joint pain) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant drug was not reported. Treatment for the event included Ibuprofen and Aleve.   Most recent FOLLOW-UP information incorporated above includes: On 26-May-2021: Significant follow up appended to AER
Vaccine expired on 02-Oct-2021 and removed from the fridge on 08-Oct-2021; administered vaccines past the expiration date; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (administered vaccines past the expiration date) and PRODUCT STORAGE ERROR (Vaccine expired on 02-Oct-2021 and removed from the fridge on 08-Oct-2021) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 040B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Oct-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (administered vaccines past the expiration date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine expired on 02-Oct-2021 and removed from the fridge on 08-Oct-2021). At the time of the report, EXPIRED PRODUCT ADMINISTERED (administered vaccines past the expiration date) and PRODUCT STORAGE ERROR (Vaccine expired on 02-Oct-2021 and removed from the fridge on 08-Oct-2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were provided.  On 08-Oct-2021, the vial was removed from fridge.  The vaccines were stored in the freezer and only removed as needed to thaw and then administered. It was mentioned that vials were taken out at a time and thawed as they did not thawed an entire box.  No treatment medications were provided.
Covid19 breakthrough.  1st vaccine given 8/23/21.  Pt presented with c/o productive cough, congestion, PNA, dehydration.  Covid+.  Treated with IV steroids and Abx.
migraine lasting 24 hours, followed by sporadic migraines for the next several days.  unexplained uterine cramping lasting several days  delayed onset of next menstruation. Was expected 6/24, did not begin until 7/1
p/vax acute pronounced joint pain & noticed more pronounced achiness in hand joints;pt still exp fatigue & minor achiness w/more pronounced achiness p/physical labor;
pain in heart; rapid heart rate; weakness; sore arm; shortness of breath /panting; tightness in chest; occasional chest pain; so weak she can't walk; headache; nausea; This spontaneous case was reported by a consumer and describes the occurrence of ANGINA PECTORIS (pain in heart) and HEART RATE INCREASED (rapid heart rate) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027A21A) for COVID-19 immunisation. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Fibromyalgia since an unknown date, Headache since an unknown date, Paralysis since an unknown date, Neuromuscular pain since an unknown date, Fatigue since an unknown date, Weakness since an unknown date and Nausea since an unknown date. Concurrent medical conditions included Mosquito bite (patient had underlying condition of West Nile Virus 5).    On 26-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced ANGINA PECTORIS (pain in heart) (seriousness criterion medically significant), HEART RATE INCREASED (rapid heart rate) (seriousness criterion medically significant), ASTHENIA (weakness), PAIN IN EXTREMITY (sore arm), DYSPNOEA (shortness of breath /panting), CHEST DISCOMFORT (tightness in chest), CHEST PAIN (occasional chest pain), GAIT DISTURBANCE (so weak she can't walk), HEADACHE (headache) and NAUSEA (nausea). At the time of the report, ANGINA PECTORIS (pain in heart), HEART RATE INCREASED (rapid heart rate), ASTHENIA (weakness), PAIN IN EXTREMITY (sore arm), DYSPNOEA (shortness of breath /panting), CHEST DISCOMFORT (tightness in chest), GAIT DISTURBANCE (so weak she can't walk), HEADACHE (headache) and NAUSEA (nausea) outcome was unknown and CHEST PAIN (occasional chest pain) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       This case concerns a 70-year-old female with serious unexpected events of angina pectoris and heart rate increased, and nonserious unexpected chest pain, chest discomfort, dyspnea, asthenia, gait disturbance, and pain in extremity and expected headache, nausea. Based on current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.; Sender's Comments: This case concerns a 70-year-old female with serious unexpected events of angina pectoris and heart rate increased, and nonserious unexpected chest pain, chest discomfort, dyspnea, asthenia, gait disturbance, and pain in extremity and expected headache, nausea. Based on current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Rash on my stomach and legs day after and still present. Day after vaccine I had a light headache and felt very tired.
pt to ER via EMS with SOB; diagnosed with AHRF with COVID pneumonia; placed on nonrebreather mask; comfort measures and meds requested as pt's condition worsened; pt expired in the hospital
ER HPI: 82 y.o. female who presents with altered mental status. Patient is transported to ED via EMS from local nursing home because of increased confusion. Patient is unable to give any pertinent history. DX: Cerebral infarction due to embolism of cerebral artery
Developed intermittent vomiting and diarrhea 1 1/2- 2weeks duration.
Post vax, this pt experienced tingling of the arm where the injection was given. A few weeks later, the tingling 'progressed to both arms and now the pt has pain in both arms, neck and back.' The pt sought unspecified medical attention. Follow-up information from a registered nurse reported that on 01/15/1999, the pt went to a physician and blood work was done and results were nml. The pt was referred to a rheumatologist. On 01/29/1999, the pt saw the rheumatologist and blood work was done and result were nml. The pt is planning on having a hepatitis B surface antibody test performed. Further information was requested.
Once patient received the COVID-19 vaccine (Pfizer) he said his arm immediately went numb and he could not feel it. The patient sat in the immunization room for a few moments until he said the feeling had passed. The patient was instructed to sit outside the immunization room for 15 minutes to be monitored. The patient said his eyes went dark, meaning he felt like he was going to pass out. After a few moments he said that feeling passed and was feeling better. We asked the patient if he wanted us to call an ambulance or his PCP and his guardian said no. Told us the patient was feeling better and was just nervous to be receiving the vaccine. The patient did not have a PCP in  because he is from .
Dose administered >12 hours post puncture; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose administered >12 hours post puncture) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 017f21a) for COVID-19 vaccination.     No Medical History information was reported.    On 07-Dec-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose administered >12 hours post puncture). On 07-Dec-2021, EXPIRED PRODUCT ADMINISTERED (Dose administered >12 hours post puncture) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   It was reported that, date the vial was initially stored in the refrigerator was 30-Nov-2021. Date the vial was first punctured was on 30-Nov-2021 time is assumed around 8AM. Date of administration of vaccine was on the 30-Nov-2021 only a fraction was given and on 07-Dec-2021, 13 patients received doses from those vials.
Patient woke up with hives on 11/26/2021 on arms, leg, parents treated with antihistamines, hives resolved for 48 hours. Patient has continued to wake up with hives, treated with antihistamines for 2 weeks and saw no hives, stopped taking antihistamines, hives returned. He has no history of hives/rashes before this, nothing else has changed (laundry detergent, sleeping arrangements, etc.)  He did also receive a flu shot on 11/18/2021 and a second Covid shot on 12/1/2021. Hives are still continuing as of Jan 4, 2022.
all symptoms started 9/25-26-2019--vomiting, chills, headache, inject site reaction (red, heat), malaise, fatigue
no advers events reported. Concerned about dosage. Child given .5 cc of FLULAVAL Adult vaccine in offce. Concerned about reactions for the patient, the adjevent and the effect on children. Call to local health department.They advised parents be notified of possible elevated temp, swelling and redness at injection site. Nurse manager placed a call to Glaxo for their input also. Message left - still awaiting responce
After she received the vaccine she started to feel itchy and had redness at injection site.   She remained itchy for several days, but it would come and go.  About two weeks after the shot; she started to break out into hives on her arms, then spread to her legs, back and head.  Her palms got red.   She took claritin and it gave her short-lived relief.  She got prescribed a medrol dose pack, she completed two packs and still no relief.  It helped while she was on it then symptoms came back once she stopped.  She has an itchy throat, swollen face.  She also has diarrhea.  Symptoms have no been for over a month and seem to be getting worse.  Following up with an allergist and her PCP today.   Dr. then prescribed Solu Medrol, IV which she had last week. While, she was receiving the treatment, she felt better.   As soon as the IV was done. She started to break out again.  Today she came into work, and her eyes were blood shot. She also has pressure in her chest and has a hard time swallowing.  She had hives on the inside of the mouth, and alongside her tongue.    She will be seeing an allergist and an infectious disease in the upcoming days.
This spontaneous report as received from a nurse refers to a male patient of unknown age. The patient's concurrent condition, medical history, drug reactions/allergies and concomitant medications were not reported. On 20-JUN-2018 the patient was vaccinated with improperly stored dose of VARIVAX (dose and frequency: not reported) (lot # N019608, expiry date: 09-JUL-2019 (reported as: 08-JUN-2270) and/or (lot # R002057, expiry date: 22-JAN-2020) and/or (lot # N027619, expiry date: 04-OCT-2019) intramuscularly for prophylaxis. The patient also received sterile diluent (MERCK) dose, frequency, lot #, expiry date: not reported). The vaccines were stored in temperature of 6 degree Fahrenheit (F) to 14 F (11 F) for 15 minutes and 15 F to 46 F (10 F-17 F) for 15 minutes. There was no previous temperature excursion reported. A digital data logger was involved. No adverse effects were reported. No product quality complaint was involved. Lot number [R002057] has been verified to be a valid lot number for varicella virus vaccine live (oka/merck).
a lot of pain under her arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (a lot of pain under her arm) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Mar-2021, the patient experienced PAIN IN EXTREMITY (a lot of pain under her arm). At the time of the report, PAIN IN EXTREMITY (a lot of pain under her arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Patient complain of left facial numbness. Reported history of sucrose and read the info on Moderna - ingredient of sucrose is listed. Vital signs collected - stable. Dr. notified. Completed assessment. Orders received to monitor patient for one hour. Symptoms lessened. Patient ambulated with walker out of office without distress noted.
Flublok was given to patient of 15 years old and that is under the age of indication, no AE; Initial information received on 09-Dec-2020 regarding an unsolicited valid non-serious case from other health professional.  This case is linked to case 2020SA355558 (Same reporter).  This case involves a 15 years old patient who was vaccinated with 0.5 ml INFLUENZA QUADRIVALENT RECOMBINANT VACCINE [FLUBLOK QIV] (lot number and expiration date not reported) and that was under the age of indication, via unknown route in unknown administration site for prophylactic vaccination (product administered to patient of inappropriate age).  Medical history, medical treatment(s), vaccination(s), concomitant medication(s) and family history were not provided.   It was a case of actual medication error due to inappropriate age at vaccine administration (same day latency).   At the time of report no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.  There will be no information on the batch number for this case.
Vaccination during pregnancy; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of EXPOSURE DURING PREGNANCY (Vaccination during pregnancy) in a 38-year-old female patient (gravida 1) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on an unknown date and the estimated date of delivery was 27-Jun-2021. On 16-Jan-2021, the patient experienced EXPOSURE DURING PREGNANCY (Vaccination during pregnancy). On 16-Jan-2021, EXPOSURE DURING PREGNANCY (Vaccination during pregnancy) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not reported by the reporter. Treatment details was not reported by the reporter.; Sender's Comments: This is a case of product exposure during pregnancy with no associated AEs for this 38-year-old female. Patient will continue to be contacted for further monitoring of AEs during the pregnancy.
vax assoc polio onset 26NOV96 fever 103, h/a, weakness in lt leg, paralysis to include lt arm;pt did not recv vax but is a contact of recipient;CDC states pt illness compatible w/paralytic poliomyelitis;post flu transverse myelitis;
Delayed cutaneous hypersensitivity (COVID arm) -- mild itchiness on days 3-8, then significant itchiness and red lesion about 3 inches in diameter around vaccine injection site.
This spontaneous report was received from an office manager and a registered nurse referring to an unknown number of patients of unknown age and gender. The patients' medical history, concurrent conditions, drug reactions/allergies and concomitant therapies were not reported. Since 24-JAN-2017, the patients had been vaccinated with an improperly stored VARIVAX vaccines, lot # L042265, expiration date: 26-OCT-2017 and lot # M024702, expiration date: 18-MAY-2018 (dose and route of administration were not reported) for prophylaxis with a temperature greater than 5 Fahrenheit degrees and less than 14 Fahrenheit degrees for 84 minutes. Additionally, previous temperature excursions were reported on an unspecified dates: greater than 5 Fahrenheit degrees but less than 14 Fahrenheit degrees for 6 minutes, greater than 14 Fahrenheit degrees but less than 46 Fahrenheit degrees for 1 hour and 48 minutes, greater than 46 Fahrenheit degrees but less than 77 Fahrenheit degrees for 2 hours and 42 minutes. No adverse effects were reported. This is one of two reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1702USA009295.
This spontaneous report was received from a nurse practitioner and refers to an unspecified number of patients of unknown age and gender. There was no information about the patients' concurrent conditions, concomitant therapies or medical histories provided. On unknown dates, the patients were vaccinated with improperly stored doses of VARIVAX lot # L037565, expiration date 29-SEP-2017 and lot# M009766, expiration date 23-APR-2018 (dose and route of administration were not reported). The VARIVAX was reconstituted with properly stored diluent (lot number and expiration date were unknown). There was no adverse effect reported. Administered doses of vaccines experienced the temperature excursion of 40 degrees Fahrenheit for 15 minutes. Data logger was involved. There were no previous excursions reported. This is one of several reports received from the same reporter. Additional information has been requested.; Sender's Comments: US-009507513-1705USA000874:
Pain during administration of vaccine that occurred on 06/12/15 that went down into elbow then resolved and noted pain again in proximal right arm near shoulder worse with abduction, extension, and certain range of motion including her using right arm to pull up pants. Persisting pain 4-3/10 intensity. Worse with ROM. No radiation-pain persisting at least 10 days after vaccination. No skin color changes.
I received the the FluMist on 01,25,05 at 0800 in the morrning. That evening 9 hours later the back of my neck felt like some one hit it with a bat. Stiffness, muscle pain, glands in neck on fire, A # 8 on the pain level. Still sore the next day. Self treated with heat, 800ml Tylenol and 500ml Motrin.
Pt developed scratch in throat approx 5 minutes after administration. Pt began to have difficulty speaking. Additional staff called into room. Client given 1 dose of epi into right deltoid. EMS called. Pt began vomiting bile. 2 minutes after administration of epi, pt began breathing normally again and able to speak. She stated she was overwhelmed with being hot, couldn't catch her breath,  wanted to speak but couldn't, and stated there was a sharp pain in her back that cut across. EMS arrived approx 10 minutes after call made to them. Pt was evaluated and no further treatment was required.
I woke up on 3/21/2021 with extremely bad pain in my right arm. I could not move my arm at all.
pt recvd vax;2 hrs after vax began to feel very tired & weak;skin turned white while got up to use bathroom & fainted; was shaky & cold afterwards;cont to feel weak & tired for 24 hrs;
CDC reports: 2yo child developed fever 104, shaking & chills 2 days p/receiving DTP/HIB immun. Duration of illness 4 days.
Patient complained of arm hurting-redness-inflammation-chills-fever-nausea-went her PCP was told it was cellulitis.
This case was reported by the mother of a consumer and described the occurrence of a bleeding skin disorder in a 2 month old female subject who was vaccinated with diphtheria and tetanus toxoids and acellular pertussis adsorbed, Hepatitis B (Recombinant) and inactivated poliovirus vaccine combined (manufacturer unspecified) for prophylaxis. On an unspecified date the subject received unspecified dose of diphtheria and tetanus toxoids and acellular pertussis adsorbed, Hepatitis B (Recombinant) and inactivated poliovirus vaccine combined (unknown). At an unspecified time after vaccination with diphtheria and tetanus toxoids and acellular pertussis adsorbed, Hepatitis B (Recombinant) and inactivated poliovirus vaccine combined, the subject developed a bleeding skin disorder. It was a level three immune system allergy. The subject was also diagnosed with a peanut allergy. At the time of reporting the outcome of the events was unspecified.
Aches in all the body; Strong headache; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Aches in all the body) and HEADACHE (Strong headache) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (no reported medical history).    On 15-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Feb-2021, the patient experienced PAIN (Aches in all the body) and HEADACHE (Strong headache). At the time of the report, PAIN (Aches in all the body) and HEADACHE (Strong headache) outcome was unknown.            No concomitant medications were provided.  No treatment information provided